| Date & Time |
Title |
Speakers |
|
05.09.2022 - 11:00am
|
An Optimized Approach to Drug Development
Take months off the development timelines of your large and small molecule discoveries. With Thermo Fisher Scientific's Quick to Care™ program, you can combine your drug substance and drug product development, demand planning and clinical trial supply execution into a single customized solution to simplify your supply chain and accelerate your discovery through clinical development.
|
Hajir Mokhtari, Senior Manager, Management Thermo Fisher Scientific
|
|
05.09.2022 - 03:00pm
|
Pharmaceutical Cannabis Global Marketplace
- Discussion of the Global Pharmaceutical Cannabis market and the history of recent growth
- Current trends in the Medical Cannabis market versus the Canadian and American experience
- Herbal Medicinal Cannabis ACM versus AIM Cannabinoid pharmaceutical trials
- Building or conforming to GMP standards for pharmaceutical cannabinoid applications
- Single cannabis API versus multiple API combinations - Delivery devices for Cannabinoid products and best practices for bio-availability
|
Michael Sassano, CEO and Chairman, Somai Pharmaceuticals
|
|
05.10.2022 - 11:00am
|
Ripple Effects of Expediting Vaccine Development
During normal times, sponsors are often challenged with qualifying outsourced manufacturing services for drugs that receive expedited market entry. However, during the COVID-19 pandemic, multiple products have received EUAs in order to bring them to the market at an even more accelerated timeline in order to address the unprecedented public health crisis of COVID-19. In her talk, Frances Zipp will discuss the quality perspective on these manufacturing relationships and will discuss the checks and balances that need to be in place between sponsors and their outsourcing partners in order to ensure continuous supply of medicines. She will discuss lessons learned and best practices for these relationships that can be applied to both accelerated approvals as well as “normal” drug supply during non-pandemic times.
|
Frances Zipp, President and CEO, Lachmann Consultants Services
|
|
05.10.2022 - 03:00pm
|
More Women in the Room
Increased numbers of women in the room are more than just placeholders... they drive better decisions, better outcomes, and better profitability.
This session will discuss:
- Where women are needed more (hint, it's everywhere)
- Why having women involved in all aspects of the business makes better business
- How to get more women involved
- How women's involvement will improve outcomes for your customers
- What does this mean for women globally
- How this affect better women's health outcomes
|
Marrisa Fayer, Ceo and Founder HerHealthEQ
|
|
05.11.2022 - 11:00am
|
Panel: Make America Pharma Again — Is Domestic Production here To Stay In a Post-Pandemic World?
The thread line: The pandemic demonstrated the need for critical life sciences products to be manufactured domestically given supply chain disruptions and reactionary policies from historic suppliers like China and India. At the same time, billions poured into the industry as the US led the race towards developing a vaccine for Covid-19. Two years later, the groundwork has been largely established in terms of increased manufacturing capacity and general industry consensus that domestic production reduces risk, impacting both pharma and biopharma companies as well as CMOs and CDMOs who operate on American soil. But as Covid-generated issues like supply chain delays are gradually elevated, is domestic production here to stay? If so, how will manufacturers keep prices competitive?
The panel will dive into current domestic R&D and production capacity, particularly of APIs, and how this influences the CMO sector.
|
Robert Bloder, Chief Business Officer, Ascendia Pharma
Chris Senanayake, CEO & CSO, TCG GreenChem, Inc.
John Pennett, Partner-in-Charge of the National Technology and Life Sciences Group, EisnerAmper
|
|
05.11.2022 - 03:00pm
|
Considerations in Extractables and Leachables Testing of Drug-Device Combination Products
This presentation will provide an overview of the differences and similarities of E&L requirements between pharmaceutical products and medical devices. The key elements regarding E&L testing design of combination products will be discussed. Several case studies on the extractables and leachables testing of combination products will be presented.
|
Dujuan Lu, Global Leader/Manager - E&L, SGS Health Science
|
|
05.12.2022 - 11:00am
|
Revealing the Marketed and Pipeline Drug Trends –What are the Outsourcing Opportunities?
A presentation which discusses novel drug approval trends and how outsourcing propensity is affected by different factors
|
Adam Bradbury, Analyst, GlobalData
|
05.12.2022 - 03:00Pm
|
Taste Masking of Bitter Drugs For Pediatric Population
- Pediatric population and their needs
- Significance of taste masking
- Taste masking strategies
- Adare's taste masking solutions
|
Srinivasan Shanmugam, Senior Director Pharmaceutical Sciences, Adare Pharmaceuticals
|